{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:22:55Z","timestamp":1788906175380,"version":"build-2803163510"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Umm Al-Qura University, Saudi Arabia","award":["26UQU4420038GSSR02"],"award-info":[{"award-number":["26UQU4420038GSSR02"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:p>Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely prescribed for type 2 diabetes mellitus and chronic weight management. With its growing global use, continuous pharmacovigilance is essential to detect emerging patterns of adverse drug reactions (ADRs). To describe the global ADRs profile of semaglutide using data from the World Health Organization\u2019s (WHO) VigiAccess pharmacovigilance database. A retrospective descriptive analysis was conducted using publicly available ADR data retrieved from the WHO-VigiAccess portal on October 18, 2025. The total number and proportion of ADRs were summarized according to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC). Demographic information, including age group, sex, geographic region, and reporting year, was reviewed descriptively. A total of 81,770 ADR reports associated with semaglutide were identified. The most frequently reported SOCs were gastrointestinal disorders (28%, n\u2005=\u200542,574), general disorders and administration site conditions (12%, n\u2005=\u200519,200), and injury, poisoning and procedural complications (11%, n\u2005=\u200516,601). Additional categories included nervous system disorders (8%), investigations (7%), and metabolism and nutrition disorders (7%). The majority of ADRs were reported among adults aged 45 to 64 years, with most originating from Europe and the Americas. Annual reporting increased markedly between 2018 and 2025, corresponding with expanded clinical use and obesity-related approvals. Global pharmacovigilance data indicate that semaglutide ADRs are primarily gastrointestinal and systemic in nature, consistent with its known pharmacological effects. Continuous monitoring is warranted to identify emerging safety signals and support optimized patient management as use expands worldwide.<\/jats:p>","DOI":"10.1097\/md.0000000000048811","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:00:39Z","timestamp":1778896839000},"page":"e48811","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-7685","authenticated-orcid":false,"given":"Nasser M.","family":"Alorfi","sequence":"first","affiliation":[{"name":"Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour M.","family":"Alourfi","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Dr. Soliman Fakeeh Hospital, Fakeeh Care Group, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Aldabbagh","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Dr. Soliman Fakeeh Hospital, Fakeeh Care Group, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed Saleh","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Dr. Soliman Fakeeh Hospital, Fakeeh Care Group, Jeddah, Saudi Arabia"},{"name":"Department of Medicine, Division of Gastroenterology, King Abdulaziz University, Jeddah , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Al Ghamdi","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Dr. Soliman Fakeeh Hospital, Fakeeh Care Group, Jeddah, Saudi Arabia"},{"name":"Department of Medicine, Division of Gastroenterology, King Abdulaziz University, Jeddah , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser M.","family":"Aldekhail","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, Nursing and Medical Sciences, Riyadh Elm University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustfa Faisal","family":"Alkhanani","sequence":"additional","affiliation":[{"name":"Biology Department, College of Sciences, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrhman M.","family":"Alansari","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Services, King Salman Medical City, Madinah Health Cluster, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris A.","family":"Alsolami","sequence":"additional","affiliation":[{"name":"Kholais General Hospital, Makkah Cluster, Ministry of Health, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihal Abdalla","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Ajman University, Ajman, United Arab Emirates"},{"name":"Center of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260904","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4\u2009mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R2-20260904","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R3-20260904","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.3390\/cimb46120872","article-title":"Spotlight on the mechanism of action of semaglutide.","volume":"46","author":"Papakonstantinou","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"R4-20260904","first-page":"61","article-title":"Clinical impact of semaglutide, a glucagon-like peptide-1 receptor agonist, on obesity management: a review.","volume":"14","author":"Alorfi","year":"2022","journal-title":"Clin Pharmacol"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13679-025-00667-3","article-title":"A multidisciplinary perspective on semaglutide treatment and medical nutrition therapy in obesity management.","volume":"14","author":"Barrea","year":"2025","journal-title":"Curr Obes Rep"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"2483607","DOI":"10.1080\/20565623.2025.2483607","article-title":"The multifaceted effects of semaglutide: exploring its broad therapeutic applications.","volume":"11","author":"Alkhatib","year":"2025","journal-title":"Future Sci OA"},{"key":"R7-20260904","doi-asserted-by":"crossref","first-page":"110881","DOI":"10.1016\/j.diabres.2023.110881","article-title":"The role of weight control in the management of type 2 diabetes mellitus: perspectives on semaglutide.","volume":"203","author":"Kurtzhals","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"R8-20260904","first-page":"29","article-title":"Semaglutide.","volume":"40","author":"Kommu","year":"2024","journal-title":"Pharma Kritik"},{"key":"R9-20260904","doi-asserted-by":"crossref","first-page":"645617","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of semaglutide in a subcutaneous and an oral formulation.","volume":"12","author":"Meier","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R10-20260904","doi-asserted-by":"crossref","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide.","volume":"12","author":"Smits,","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with Type 2 diabetes: the PIONEER 8 trial.","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"R12-20260904","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5144\/0256-4947.2024.361","article-title":"Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.","volume":"44","author":"Butt","year":"2024","journal-title":"Ann Saudi Med"},{"key":"R13-20260904","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/dom.14990","article-title":"Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.","volume":"25","author":"Aroda","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R14-20260904","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once\u2010weekly semaglutide 2.4\u2009mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.","volume":"24","author":"Wharton","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R15-20260904","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss.","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"R16-20260904","doi-asserted-by":"crossref","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system.","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"key":"R17-20260904","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis.","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26502\/aimr.0189","article-title":"Semaglutide: double-edged sword with risks and benefits.","volume":"8","author":"Pillarisetti","year":"2025","journal-title":"Arch Internal Med Res"},{"key":"R19-20260904","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"R20-20260904","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10571-025-01534-4","article-title":"Beyond diabetes: semaglutide\u2019s role in modulating mood disorders through neuroinflammation pathways.","volume":"45","author":"Pi\u0105tkowska-Chmiel","year":"2025","journal-title":"Cell Mol Neurobiol"},{"key":"R21-20260904","doi-asserted-by":"crossref","first-page":"e70661","DOI":"10.1002\/brb3.70661","article-title":"Efficacy and safety of glucagon-like peptide-1 agonists for psychiatric symptoms: a systematic review.","volume":"15","author":"Meshkat","year":"2025","journal-title":"Brain Behav"},{"key":"R22-20260904","doi-asserted-by":"crossref","first-page":"2","DOI":"10.52667\/2712-9179-2024-4-2-11","article-title":"Neuroprotective activity of GLP-1 analogues: general understanding of implementation mechanisms.","volume":"4","author":"Golovina","year":"2024","journal-title":"Personalized Psychiatry Neurol"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"113537","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study.","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R24-20260904","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries.","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R25-20260904","doi-asserted-by":"crossref","first-page":"e2526321","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes.","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R26-20260904","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"R27-20260904","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clnu.2025.06.011","article-title":"Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: a vigibase study.","volume":"51","author":"Nishida","year":"2025","journal-title":"Clin Nutr"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:00:26Z","timestamp":1788530426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":27,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048811","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2025-10-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}